Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Eclinicalmedicine|March 10, 2023
Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort studyNeha Korde, Elizabet Tavitian, Donna Mastey, et al.
Blood Cancer Journal|May 31, 2024
Comparison of infectious complications with BCMA-directed therapies in multiple myelomaKarthik Nath, Tala Shekarkhand, David Nemirovsky, et al.
American Journal of Hematology|January 2, 2023
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approachMatthew J Pianko, Timothy Tiutan, Andriy Derkach, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2013
Venous thromboembolic diseaseMichael B Streiff, Paula L Bockenstedt, Spero R Cataland, et al.
JCO Oncology Practice|September 16, 2025
Defining the Rates of Cytokine Release Syndrome Associated With Talquetamab Step-up DosesIssam S Hamadeh, Lisa Modelevsky, Amelia Chan, et al.
Blood Advances|April 10, 2024
Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapyIssam S Hamadeh, Tala Shekarkhand, Colin Rueda, et al.
Medrxiv : the Preprint Server for Health Sciences|June 25, 2020
COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centersMalin Hultcrantz, Joshua Richter, Cara Rosenbaum, et al.
Blood Advances|May 2, 2025
Outcomes in Frail Patients Receiving BCMA-directed Bispecific Antibodies for Relapsed/Refractory Multiple MyelomaBenjamin O Adegbite, Carlyn Rose Tan, Tala Shekarkhand, et al.
Blood Advances|October 25, 2023
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myelomaRoss S Firestone, Devin McAvoy, Tala Shekarkhand, et al.
Blood Advances|February 17, 2026
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMMKylee H Maclachlan, Carlyn Rose Tan, Tala Shekarkhand, et al.
Pageof 8